Symbols / MRK $120.85 -0.02% Merck & Co., Inc.

Healthcare • Drug Manufacturers - General • United States • NYQ
MRK Chart
About

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Drug Manufacturers - Gen Market Cap 298.79B
Enterprise Value 334.86B Income 18.25B Sales 65.01B
Book/sh 21.26 Cash/sh 5.89 Dividend Yield 281.00%
Payout 45.05% Employees 73000 IPO —
P/E 16.60 Forward P/E 12.40 PEG —
P/S 4.60 P/B 5.68 P/C —
EV/EBITDA 11.51 EV/Sales 5.15 Quick Ratio 0.96
Current Ratio 1.54 Debt/Eq 95.96 LT Debt/Eq —
EPS (ttm) 7.28 EPS next Y 9.74 EPS Growth -19.30%
Revenue Growth 5.00% Earnings 2026-04-30 ROA 12.04%
ROE 36.88% ROIC — Gross Margin 77.21%
Oper. Margin 32.77% Profit Margin 28.08% Shs Outstand 2.47B
Shs Float 2.47B Short Float 1.31% Short Ratio 2.95
Short Interest — 52W High 125.14 52W Low 73.31
Beta 0.28 Avg Volume 11.84M Volume 4.89M
Target Price $128.59 Recom Buy Prev Close $120.87
Price $120.85 Change -0.02%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$128.59
Mean price target
2. Current target
$120.85
Latest analyst target
3. DCF / Fair value
$86.54
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$120.85
Low
$100.00
High
$150.00
Mean
$128.59

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-06 main JP Morgan Overweight → Overweight $135
2026-03-30 reit RBC Capital Outperform → Outperform $142
2026-03-20 main Citigroup Neutral → Neutral $125
2026-03-12 main Wells Fargo Overweight → Overweight $150
2026-02-25 init RBC Capital — → Outperform $142
2026-02-20 init Barclays — → Overweight $140
2026-02-09 main Freedom Broker Hold → Hold $110
2026-02-06 main Guggenheim Buy → Buy $140
2026-02-04 main Citigroup Neutral → Neutral $120
2026-02-04 main Cantor Fitzgerald Neutral → Neutral $120
2026-02-04 main Wells Fargo Overweight → Overweight $135
2026-01-27 main Citigroup Neutral → Neutral $115
2026-01-20 main TD Cowen Hold → Hold $120
2026-01-08 up Wolfe Research Peer Perform → Outperform $135
2026-01-07 main UBS Buy → Buy $130
2026-01-07 main Citigroup Neutral → Neutral $110
2025-12-18 up BMO Capital Market Perform → Outperform $130
2025-12-15 main B of A Securities Buy → Buy $120
2025-12-12 main Morgan Stanley Equal-Weight → Equal-Weight $102
2025-12-04 main Scotiabank Sector Outperform → Sector Outperform $120
News
RSS: Latest MRK news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-12 GUINDO CHIRFI Officer — 10,000 $121.46 $1,214,562
2026-02-10 LI DEAN Y Officer — 10,235 $117.52 $1,202,844
2026-02-09 ZACHARY JENNIFER L General Counsel — 121,573 $119.15 $14,485,690
2026-02-09 GUINDO CHIRFI Officer — 10,000 $118.41 $1,184,101
2026-02-09 ZACHARY JENNIFER L General Counsel — 121,573 $119.15 $14,485,690
2026-02-06 OOSTHUIZEN JOHANNES JACOBUS Officer — 15,000 $121.87 $1,827,992
2026-02-06 WILLIAMS DAVID MICHAEL Chief Technology Officer — 5,000 $121.90 $609,525
2026-02-06 DELUCA RICHARD ROBERT JR. Officer — 37,685 $120.92 $4,557,025
2026-02-06 WILLIAMS DAVID MICHAEL Chief Technology Officer — 5,000 $77.62 $388,100
2026-02-05 GUINDO CHIRFI Officer — 20,000 $121.88 $2,437,676
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
65,011.00
+1.31%
64,168.00
+6.74%
60,115.00
+1.40%
59,283.00
Operating Revenue
65,011.00
+1.31%
64,168.00
+6.74%
60,115.00
+1.40%
59,283.00
Cost Of Revenue
16,382.00
+7.83%
15,193.00
-5.79%
16,126.00
-7.38%
17,411.00
Reconciled Cost Of Revenue
16,382.00
+7.83%
15,193.00
-5.79%
16,126.00
-7.38%
17,411.00
Gross Profit
48,629.00
-0.71%
48,975.00
+11.33%
43,989.00
+5.06%
41,872.00
Operating Expense
26,522.00
-7.76%
28,754.00
-29.93%
41,035.00
+73.95%
23,590.00
Research And Development
15,789.00
-11.98%
17,938.00
-41.25%
30,531.00
+125.35%
13,548.00
Selling General And Administration
10,733.00
-0.77%
10,816.00
+2.97%
10,504.00
+4.60%
10,042.00
Total Expenses
42,904.00
-2.37%
43,947.00
-23.12%
57,161.00
+39.41%
41,001.00
Operating Income
22,107.00
+9.33%
20,221.00
+584.53%
2,954.00
-83.84%
18,282.00
EBITDA
28,262.00
+9.94%
25,706.00
+272.17%
6,907.00
-67.60%
21,315.00
Normalized EBITDA
29,106.00
+10.97%
26,228.00
+248.04%
7,536.00
-67.67%
23,308.00
Reconciled Depreciation
5,838.00
+29.76%
4,499.00
+16.19%
3,872.00
-0.95%
3,909.00
EBIT
22,424.00
+5.74%
21,207.00
+598.75%
3,035.00
-82.56%
17,406.00
Total Unusual Items
-844.00
-61.69%
-522.00
+17.01%
-629.00
+68.44%
-1,993.00
Total Unusual Items Excluding Goodwill
-844.00
-61.69%
-522.00
+17.01%
-629.00
+68.44%
-1,993.00
Special Income Charges
-889.00
-187.70%
-309.00
+48.41%
-599.00
-77.74%
-337.00
Restructuring And Mergern Acquisition
889.00
+187.70%
309.00
-48.41%
599.00
+77.74%
337.00
Net Income
18,254.00
+6.64%
17,117.00
+4589.59%
365.00
-97.49%
14,519.00
Pretax Income
21,067.00
+5.67%
19,936.00
+955.37%
1,889.00
-88.51%
16,444.00
Net Non Operating Interest Income Expense
-1,014.00
-18.46%
-856.00
-9.60%
-781.00
+2.98%
-805.00
Interest Expense Non Operating
1,357.00
+6.77%
1,271.00
+10.91%
1,146.00
+19.13%
962.00
Net Interest Income
-1,014.00
-18.46%
-856.00
-9.60%
-781.00
+2.98%
-805.00
Interest Expense
1,357.00
+6.77%
1,271.00
+10.91%
1,146.00
+19.13%
962.00
Interest Income Non Operating
343.00
-17.35%
415.00
+13.70%
365.00
+132.48%
157.00
Interest Income
343.00
-17.35%
415.00
+13.70%
365.00
+132.48%
157.00
Other Income Expense
-26.00
-104.55%
571.00
+301.06%
-284.00
+72.51%
-1,033.00
Other Non Operating Income Expenses
818.00
-25.16%
1,093.00
+216.81%
345.00
-64.06%
960.00
Gain On Sale Of Security
45.00
+121.13%
-213.00
-610.00%
-30.00
+98.19%
-1,656.00
Tax Provision
2,804.00
+0.04%
2,803.00
+85.38%
1,512.00
-21.17%
1,918.00
Tax Rate For Calcs
0.00
-5.33%
0.00
-33.05%
0.00
+79.49%
0.00
Tax Effect Of Unusual Items
-112.34
-53.06%
-73.39
+44.44%
-132.09
+43.35%
-233.18
Net Income Including Noncontrolling Interests
18,263.00
+6.60%
17,133.00
+4444.56%
377.00
-97.40%
14,526.00
Net Income From Continuing Operation Net Minority Interest
18,254.00
+6.64%
17,117.00
+4589.59%
365.00
-97.49%
14,519.00
Net Income From Continuing And Discontinued Operation
18,254.00
+6.64%
17,117.00
+4589.59%
365.00
-97.49%
14,519.00
Net Income Continuous Operations
18,263.00
+6.60%
17,133.00
+4444.56%
377.00
-97.40%
14,526.00
Net Income Discontinuous Operations
—
—
0.00
0.00
Minority Interests
-9.00
+43.75%
-16.00
-33.33%
-12.00
-71.43%
-7.00
Normalized Income
18,985.66
+8.08%
17,565.61
+1937.99%
861.91
-94.71%
16,278.82
Net Income Common Stockholders
18,254.00
+6.64%
17,117.00
+4589.59%
365.00
-97.49%
14,519.00
Diluted EPS
7.28
+8.01%
6.74
+4714.29%
0.14
-97.55%
5.71
Basic EPS
7.38
+8.93%
6.77
+4737.10%
0.14
-97.56%
5.73
Basic Average Shares
2,474.63
-2.10%
2,527.64
-3.05%
2,607.14
+2.97%
2,532.00
Diluted Average Shares
2,507.00
-1.34%
2,541.00
-2.54%
2,607.14
+2.56%
2,542.00
Diluted NI Availto Com Stockholders
18,254.00
+6.64%
17,117.00
+4589.59%
365.00
-97.49%
14,519.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
136,866.00
+16.87%
117,106.00
+9.78%
106,675.00
-2.28%
109,160.00
Current Assets
43,516.00
+12.21%
38,782.00
+20.56%
32,168.00
-9.95%
35,722.00
Cash Cash Equivalents And Short Term Investments
14,565.00
+6.40%
13,689.00
+92.99%
7,093.00
-46.23%
13,192.00
Cash And Cash Equivalents
14,565.00
+9.99%
13,242.00
+93.57%
6,841.00
-46.11%
12,694.00
Other Short Term Investments
0.00
-100.00%
447.00
+77.38%
252.00
-49.40%
498.00
Receivables
11,775.00
+14.57%
10,278.00
-0.69%
10,349.00
+9.51%
9,450.00
Accounts Receivable
11,775.00
+14.57%
10,278.00
-0.69%
10,349.00
+9.51%
9,450.00
Gross Accounts Receivable
11,872.00
+14.52%
10,367.00
-0.67%
10,437.00
+9.61%
9,522.00
Allowance For Doubtful Accounts Receivable
-97.00
-8.99%
-89.00
-1.14%
-88.00
-22.22%
-72.00
Inventory
6,658.00
+8.99%
6,109.00
-3.92%
6,358.00
+7.56%
5,911.00
Assets Held For Sale Current
—
—
—
—
Other Current Assets
10,518.00
+20.81%
8,706.00
+4.04%
8,368.00
+16.72%
7,169.00
Total Non Current Assets
93,350.00
+19.18%
78,324.00
+5.12%
74,507.00
+1.46%
73,438.00
Net PPE
25,316.00
+6.46%
23,779.00
+3.16%
23,051.00
+7.60%
21,422.00
Gross PPE
47,230.00
+10.01%
42,934.00
+3.91%
41,317.00
+4.85%
39,407.00
Accumulated Depreciation
-21,914.00
-14.40%
-19,155.00
-4.87%
-18,266.00
-1.56%
-17,985.00
Properties
0.00
0.00
0.00
0.00
Land And Improvements
321.00
+4.56%
307.00
-5.83%
326.00
+10.51%
295.00
Buildings And Improvements
17,983.00
+9.92%
16,360.00
+9.31%
14,966.00
+13.67%
13,166.00
Machinery Furniture Equipment
19,760.00
+8.08%
18,283.00
+2.93%
17,763.00
+5.98%
16,760.00
Construction In Progress
9,166.00
+14.80%
7,984.00
-3.36%
8,262.00
-10.06%
9,186.00
Goodwill And Other Intangible Assets
48,260.00
+26.87%
38,038.00
-2.98%
39,208.00
-5.46%
41,473.00
Goodwill
21,579.00
-0.41%
21,668.00
+2.22%
21,197.00
-0.03%
21,204.00
Other Intangible Assets
26,681.00
+62.99%
16,370.00
-9.11%
18,011.00
-11.14%
20,269.00
Investments And Advances
956.00
+106.48%
463.00
+83.73%
252.00
-75.17%
1,015.00
Other Non Current Assets
18,818.00
+17.29%
16,044.00
+33.74%
11,996.00
+25.90%
9,528.00
Total Liabilities Net Minority Interest
84,204.00
+19.04%
70,734.00
+2.45%
69,040.00
+9.41%
63,102.00
Current Liabilities
28,327.00
-0.33%
28,420.00
+10.61%
25,694.00
+6.00%
24,239.00
Payables And Accrued Expenses
25,738.00
-0.13%
25,771.00
+5.96%
24,322.00
+9.10%
22,293.00
Payables
11,270.00
+11.84%
10,077.00
+17.78%
8,556.00
+5.19%
8,134.00
Accounts Payable
4,404.00
+7.97%
4,079.00
+4.00%
3,922.00
-8.02%
4,264.00
Dividends Payable
2,140.00
+2.69%
2,084.00
+4.99%
1,985.00
+5.36%
1,884.00
Current Accrued Expenses
14,468.00
-7.81%
15,694.00
-0.46%
15,766.00
+11.35%
14,159.00
Total Tax Payable
4,726.00
+20.75%
3,914.00
+47.75%
2,649.00
+33.38%
1,986.00
Income Tax Payable
4,726.00
+20.75%
3,914.00
+47.75%
2,649.00
+33.38%
1,986.00
Current Debt And Capital Lease Obligation
2,589.00
-2.27%
2,649.00
+93.08%
1,372.00
-29.50%
1,946.00
Current Debt
2,589.00
-2.27%
2,649.00
+93.08%
1,372.00
-29.50%
1,946.00
Total Non Current Liabilities Net Minority Interest
55,877.00
+32.05%
42,314.00
-2.38%
43,346.00
+11.54%
38,863.00
Liabilities Heldfor Sale Non Current
—
—
—
—
Long Term Debt And Capital Lease Obligation
46,750.00
+35.66%
34,462.00
+2.31%
33,683.00
+17.18%
28,745.00
Long Term Debt
46,750.00
+35.66%
34,462.00
+2.31%
33,683.00
+17.18%
28,745.00
Non Current Deferred Liabilities
1,439.00
+3.75%
1,387.00
+59.24%
871.00
-51.48%
1,795.00
Non Current Deferred Taxes Liabilities
1,439.00
+3.75%
1,387.00
+59.24%
871.00
-51.48%
1,795.00
Other Non Current Liabilities
7,688.00
+18.92%
6,465.00
-26.47%
8,792.00
+5.63%
8,323.00
Stockholders Equity
52,606.00
+13.59%
46,313.00
+23.24%
37,581.00
-18.29%
45,991.00
Common Stock Equity
52,606.00
+13.59%
46,313.00
+23.24%
37,581.00
-18.29%
45,991.00
Capital Stock
1,788.00
+0.00%
1,788.00
+0.00%
1,788.00
+0.00%
1,788.00
Common Stock
1,788.00
+0.00%
1,788.00
+0.00%
1,788.00
+0.00%
1,788.00
Share Issued
3,577.10
+0.00%
3,577.10
+0.00%
3,577.10
+0.00%
3,577.10
Ordinary Shares Number
2,474.63
-2.10%
2,527.64
-0.16%
2,531.63
-0.24%
2,537.83
Treasury Shares Number
1,102.48
+5.05%
1,049.47
+0.38%
1,045.47
+0.60%
1,039.27
Additional Paid In Capital
45,029.00
+0.73%
44,704.00
+0.44%
44,509.00
+0.29%
44,379.00
Retained Earnings
73,075.00
+15.87%
63,069.00
+17.02%
53,895.00
-11.76%
61,081.00
Gains Losses Not Affecting Retained Earnings
-4,287.00
+13.31%
-4,945.00
+4.19%
-5,161.00
-8.24%
-4,768.00
Treasury Stock
62,999.00
+8.05%
58,303.00
+1.48%
57,450.00
+1.70%
56,489.00
Minority Interest
56.00
-5.08%
59.00
+9.26%
54.00
-19.40%
67.00
Other Equity Adjustments
-4,287.00
+13.31%
-4,945.00
+4.19%
-5,161.00
-8.24%
-4,768.00
Total Equity Gross Minority Interest
52,662.00
+13.56%
46,372.00
+23.22%
37,635.00
-18.29%
46,058.00
Total Capitalization
99,356.00
+23.00%
80,775.00
+13.35%
71,264.00
-4.65%
74,736.00
Working Capital
15,189.00
+46.58%
10,362.00
+60.06%
6,474.00
-43.62%
11,483.00
Invested Capital
101,945.00
+22.20%
83,424.00
+14.85%
72,636.00
-5.28%
76,682.00
Total Debt
49,339.00
+32.95%
37,111.00
+5.87%
35,055.00
+14.22%
30,691.00
Net Debt
34,774.00
+45.69%
23,869.00
-15.40%
28,214.00
+56.77%
17,997.00
Net Tangible Assets
4,346.00
-47.48%
8,275.00
+608.60%
-1,627.00
-136.01%
4,518.00
Tangible Book Value
4,346.00
-47.48%
8,275.00
+608.60%
-1,627.00
-136.01%
4,518.00
Available For Sale Securities
956.00
+106.48%
463.00
+83.73%
252.00
—
Investmentin Financial Assets
956.00
+106.48%
463.00
+83.73%
252.00
—
Trading Securities
—
463.00
+83.73%
252.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
16,472.00
-23.27%
21,468.00
+65.06%
13,006.00
-31.89%
19,095.00
Cash Flow From Continuing Operating Activities
16,472.00
-23.27%
21,468.00
+65.06%
13,006.00
-31.89%
19,095.00
Cash From Discontinued Operating Activities
—
—
0.00
0.00
Net Income From Continuing Operations
18,263.00
+6.60%
17,133.00
+4444.56%
377.00
-97.40%
14,526.00
Depreciation Amortization Depletion
5,838.00
+29.76%
4,499.00
+16.19%
3,872.00
-0.95%
3,909.00
Depreciation
3,045.00
+44.72%
2,104.00
+15.10%
1,828.00
+0.22%
1,824.00
Amortization Cash Flow
2,793.00
+16.62%
2,395.00
+17.17%
2,044.00
-1.97%
2,085.00
Depreciation And Amortization
5,838.00
+29.76%
4,499.00
+16.19%
3,872.00
-0.95%
3,909.00
Amortization Of Intangibles
2,793.00
+16.62%
2,395.00
+17.17%
2,044.00
-1.97%
2,085.00
Other Non Cash Items
511.00
-87.12%
3,966.00
-66.29%
11,764.00
+804.23%
1,301.00
Stock Based Compensation
820.00
+7.75%
761.00
+17.98%
645.00
+19.22%
541.00
Asset Impairment Charge
55.00
+41.03%
39.00
-95.08%
792.00
-54.72%
1,749.00
Deferred Tax
-1,671.00
-33.79%
-1,249.00
+34.23%
-1,899.00
-21.11%
-1,568.00
Deferred Income Tax
-1,671.00
-33.79%
-1,249.00
+34.23%
-1,899.00
-21.11%
-1,568.00
Operating Gains Losses
-368.00
-2528.57%
-14.00
+95.88%
-340.00
-123.96%
1,419.00
Gain Loss On Investment Securities
-368.00
-2528.57%
-14.00
+95.88%
-340.00
-123.96%
1,419.00
Change In Working Capital
-6,976.00
-90.24%
-3,667.00
-66.30%
-2,205.00
+20.74%
-2,782.00
Change In Receivables
-1,090.00
-346.72%
-244.00
+78.75%
-1,148.00
-78.26%
-644.00
Changes In Account Receivables
-1,090.00
-346.72%
-244.00
+78.75%
-1,148.00
-78.26%
-644.00
Change In Inventory
-1,180.00
-41.32%
-835.00
-2.33%
-816.00
-406.83%
-161.00
Change In Payables And Accrued Expense
-1,594.00
-41.94%
-1,123.00
-169.45%
1,617.00
+3843.90%
41.00
Change In Accrued Expense
-1,841.00
+20.92%
-2,328.00
-230.57%
1,783.00
+3666.00%
-50.00
Change In Payable
247.00
-79.50%
1,205.00
+825.90%
-166.00
-282.42%
91.00
Change In Account Payable
110.00
-39.56%
182.00
+147.89%
-380.00
-31.49%
-289.00
Change In Other Working Capital
-3,307.00
-133.55%
-1,416.00
+38.81%
-2,314.00
-57.09%
-1,473.00
Change In Other Current Liabilities
195.00
+497.96%
-49.00
-110.75%
456.00
+183.67%
-545.00
Investing Cash Flow
-13,741.00
-77.67%
-7,734.00
+45.08%
-14,083.00
-183.93%
-4,960.00
Cash Flow From Continuing Investing Activities
-13,741.00
-77.67%
-7,734.00
+45.08%
-14,083.00
-183.93%
-4,960.00
Cash From Discontinued Investing Activities
—
—
0.00
0.00
Capital Expenditure
-4,112.00
-21.95%
-3,372.00
+12.71%
-3,863.00
+11.96%
-4,388.00
Capital Expenditure Reported
-4,112.00
-21.95%
-3,372.00
+12.71%
-3,863.00
+11.96%
-4,388.00
Net Investment Purchase And Sale
471.00
+431.69%
-142.00
-107.68%
1,848.00
+482.61%
-483.00
Purchase Of Investment
-1,207.00
-132.56%
-519.00
+45.65%
-955.00
+20.68%
-1,204.00
Sale Of Investment
1,678.00
+345.09%
377.00
-86.55%
2,803.00
+288.77%
721.00
Net Business Purchase And Sale
-10,042.00
-145.35%
-4,093.00
+65.98%
-12,032.00
0.00
Purchase Of Business
-10,042.00
-145.35%
-4,093.00
+65.98%
-12,032.00
0.00
Net Other Investing Changes
-58.00
+54.33%
-127.00
-252.78%
-36.00
+59.55%
-89.00
Financing Cash Flow
-1,922.00
+72.67%
-7,032.00
-46.20%
-4,810.00
+47.25%
-9,119.00
Cash Flow From Continuing Financing Activities
-1,922.00
+72.67%
-7,032.00
-46.20%
-4,810.00
+47.25%
-9,119.00
Net Issuance Payments Of Debt
11,377.00
+392.72%
2,309.00
-44.81%
4,184.00
+285.87%
-2,251.00
Issuance Of Debt
13,880.00
+285.66%
3,599.00
-39.40%
5,939.00
0.00
Repayment Of Debt
-2,503.00
-94.03%
-1,290.00
+26.50%
-1,755.00
+22.03%
-2,251.00
Long Term Debt Issuance
13,880.00
+285.66%
3,599.00
-39.40%
5,939.00
0.00
Long Term Debt Payments
-2,503.00
-94.03%
-1,290.00
+26.50%
-1,755.00
+22.03%
-2,251.00
Net Long Term Debt Issuance
11,377.00
+392.72%
2,309.00
-44.81%
4,184.00
+285.87%
-2,251.00
Net Short Term Debt Issuance
—
—
0.00
0.00
Net Common Stock Issuance
-5,084.00
-289.28%
-1,306.00
+2.97%
-1,346.00
0.00
Common Stock Payments
-5,084.00
-289.28%
-1,306.00
+2.97%
-1,346.00
0.00
Common Stock Dividend Paid
-8,176.00
-4.29%
-7,840.00
-5.31%
-7,445.00
-6.18%
-7,012.00
Cash Dividends Paid
-8,176.00
-4.29%
-7,840.00
-5.31%
-7,445.00
-6.18%
-7,012.00
Repurchase Of Capital Stock
-5,084.00
-289.28%
-1,306.00
+2.97%
-1,346.00
0.00
Proceeds From Stock Option Exercised
92.00
-48.02%
177.00
+41.60%
125.00
-67.45%
384.00
Net Other Financing Charges
-131.00
+64.78%
-372.00
-13.41%
-328.00
-36.67%
-240.00
Changes In Cash
809.00
-87.93%
6,702.00
+213.84%
-5,887.00
-217.36%
5,016.00
Effect Of Exchange Rate Changes
563.00
+292.15%
-293.00
-1373.91%
23.00
+105.61%
-410.00
Beginning Cash Position
13,318.00
+92.76%
6,909.00
-45.91%
12,773.00
+56.40%
8,167.00
End Cash Position
14,690.00
+10.30%
13,318.00
+92.76%
6,909.00
-45.91%
12,773.00
Free Cash Flow
12,360.00
-31.70%
18,096.00
+97.92%
9,143.00
-37.83%
14,707.00
Change In Income Tax Payable
137.00
-86.61%
1,023.00
+378.04%
214.00
-43.68%
380.00
Change In Tax Payable
137.00
-86.61%
1,023.00
+378.04%
214.00
-43.68%
380.00
Earnings Losses From Equity Investments
—
—
-340.00
-123.96%
1,419.00
Other Cash Adjustment Outside Changein Cash
—
—
—
0.00
Cash From Discontinued Financing Activities
—
—
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category